These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

523 related items for PubMed ID: 11484981

  • 1. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
    Taponeco F, Curcio C, Giuntini A, Nardini V, Fornaciari G, Artini PG, D'Ambrogio G, Genazzani AR.
    J Exp Clin Cancer Res; 2001 Jun; 20(2):239-46. PubMed ID: 11484981
    [Abstract] [Full Text] [Related]

  • 2. Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas.
    Osmak M, Babić D, Abramić M, Milicić D, Vrhovec I, Skrk J.
    Neoplasma; 2001 Jun; 48(6):462-7. PubMed ID: 11949838
    [Abstract] [Full Text] [Related]

  • 3. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
    Steiner E, Pollow K, Hasenclever D, Schormann W, Hermes M, Schmidt M, Puhl A, Brulport M, Bauer A, Petry IB, Koelbl H, Hengstler JG.
    Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
    [Abstract] [Full Text] [Related]

  • 4. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 5. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL.
    Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
    [Abstract] [Full Text] [Related]

  • 6. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC, Holzscheiter L, Kotzsch M, Luther T, Kiechle-Bahat M, Sweep FC, Span PN, Schmitt M, Magdolen V.
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [Abstract] [Full Text] [Related]

  • 7. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
    Cho JY, Chung HC, Noh SH, Roh JK, Min JS, Kim BS.
    Cancer; 1997 Mar 01; 79(5):878-83. PubMed ID: 9041148
    [Abstract] [Full Text] [Related]

  • 8. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
    Konecny G, Untch M, Pihan A, Kimmig R, Gropp M, Stieber P, Hepp H, Slamon D, Pegram M.
    Clin Cancer Res; 2001 Jun 01; 7(6):1743-9. PubMed ID: 11410515
    [Abstract] [Full Text] [Related]

  • 9. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
    Foca C, Moses EK, Quinn MA, Rice GE.
    Gynecol Oncol; 2000 Nov 01; 79(2):244-50. PubMed ID: 11063652
    [Abstract] [Full Text] [Related]

  • 10. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.
    Kobayashi H, Fujishiro S, Terao T.
    Cancer Res; 1994 Dec 15; 54(24):6539-48. PubMed ID: 7987854
    [Abstract] [Full Text] [Related]

  • 11. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
    Zhao EM, Han DM, Yu ZK, Fan EZ, Li Y.
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb 15; 38(1):39-42. PubMed ID: 12778766
    [Abstract] [Full Text] [Related]

  • 12. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
    Stabuc B, Markovic J, Bartenjev I, Vrhovec I, Medved U, Kocijancic B.
    Oncol Rep; 2003 Feb 15; 10(3):635-9. PubMed ID: 12684636
    [Abstract] [Full Text] [Related]

  • 13. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
    Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H.
    Cancer Res; 1994 May 15; 54(10):2527-30. PubMed ID: 8168072
    [Abstract] [Full Text] [Related]

  • 14. [Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia].
    Gerstein ES, Gritsaenko EV, Shcherbakov ME, Shcherbakov AM, Ognerudov NA, Kushlinskiĭ NE.
    Vopr Onkol; 2003 May 15; 49(6):725-9. PubMed ID: 14976916
    [Abstract] [Full Text] [Related]

  • 15. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
    Fujii T, Obara T, Tanno S, Ura H, Kohgo Y.
    Hepatogastroenterology; 1999 May 15; 46(28):2299-308. PubMed ID: 10521987
    [Abstract] [Full Text] [Related]

  • 16. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
    Harbeck N, Kates RE, Look MP, Meijer-Van Gelder ME, Klijn JG, Krüger A, Kiechle M, Jänicke F, Schmitt M, Foekens JA.
    Cancer Res; 2002 Aug 15; 62(16):4617-22. PubMed ID: 12183417
    [Abstract] [Full Text] [Related]

  • 17. The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis.
    Pappot H, Pedersen AN, Brünner N, Christensen IJ.
    Lung Cancer; 2006 Feb 15; 51(2):193-200. PubMed ID: 16325301
    [Abstract] [Full Text] [Related]

  • 18. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
    Hundsdorfer B, Zeilhofer HF, Bock KP, Dettmar P, Schmitt M, Kolk A, Pautke C, Horch HH.
    J Craniomaxillofac Surg; 2005 Jun 15; 33(3):191-6. PubMed ID: 15878520
    [Abstract] [Full Text] [Related]

  • 19. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Geurts-Moespot A, van Tienoven DT, Beex LV, Sweep FC.
    Cancer; 2004 Aug 01; 101(3):486-94. PubMed ID: 15274061
    [Abstract] [Full Text] [Related]

  • 20. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL.
    J Pathol; 2001 Sep 01; 195(2):236-43. PubMed ID: 11592104
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.